Shionogi – GARDP, Cefiderocol License Agreement

• Post author:GHIAA Admin
• Post published:July 8, 2022
• Post category:

Continue ReadingShionogi – GARDP, Cefiderocol License Agreement

NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement

• Post author:GHIAA Admin
• Post published:June 29, 2022
• Post category:

Continue ReadingNIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement

Elkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement

• Post author:GHIAA Admin
• Post published:May 31, 2022
• Post category:

Continue ReadingElkurt – Ocean Biomedical, Malaria Vaccine, Exclusive License Agreement

CSIC – MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement

• Post author:GHIAA Admin
• Post published:May 23, 2022
• Post category:

Continue ReadingCSIC – MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement

Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement

• Post author:GHIAA Admin
• Post published:March 3, 2022
• Post category:

Continue ReadingBiological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement

Merck – MPP, Molnupiravir License Agreement

• Post author:GHIAA Admin
• Post published:November 22, 2021
• Post category:

Continue ReadingMerck – MPP, Molnupiravir License Agreement

University of Liverpool – MPP, Solid Drug Nanoparticle Technology License Agreement

• Post author:GHIAA Editor
• Post published:May 21, 2020
• Post category:

Continue ReadingUniversity of Liverpool – MPP, Solid Drug Nanoparticle Technology License Agreement